Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

NCT00126503 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

73

Enrollment

NIH

Sponsor class

Conditions

Chromophobe Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Recurrent Renal Cell Carcinoma
Sarcomatoid Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Sorafenib Tosylate
OTHER: Pharmacological Study
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)